NCT05176548|Unknown
Registry of Patients with Suspected Amyloidosis in Heart Failure
Regamic
Loading search results
Regamic
Sponsor study identifier
observational
450
1 country
1
Study Start
January 15, 2022
Actual (reported)Primary Completion
March 31, 2024
Actual (reported)Study Completion
December 31, 2025
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
Observational multicenter registry of cohorts with follow-up. Patients with heart failure, age ≥ 18 years, with clinical suspicion of cardiac amyloidosis and any LVEF value, treated in the field of Internal Medicine. Initially, a duration of two years was established to recruit at least 150 patients in the group with AC, and a follow-up of two years. Upon completion of the two years of follow-up, the continuity or completion of the registry will be assessed.
Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.
December 31, 2025
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
Click on a node to explore related trials.
Some registry-reported names shown below are not yet linked in this graph.
Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.
November 8, 2021
Actual (reported)January 4, 2022
Actual (reported)January 15, 2022
Actual (reported)March 31, 2024
Actual (reported)December 31, 2025
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
Differential characteristics between two groups
Number of biopsies performed between both groups.
Up to two years
Prognostic differences between both groups
Up to two years
Prognostic differences between two groups
Up to Two years
Patients in whom Cardiac Amyloidosis is confirmed
Patients in whom Cardiac Amyloidosis is ruled out
Patients with confirmed ATTR type CA will undergo a study of mutations in the TTR gene
Registry-reported names are shown in full. Names without a link have not yet been matched to a Syfrah profile.
Diagnostic Test: Bone-cardiac scintigraphy with Tc-DPD (or similar: Tc-PYP or Tc-HMDP) to evaluate the degree of cardiac uptake from 0 to 3 degrees. Diagnostic Test: Proteinogram and serum immunoglobulins. Light chains free in serum -Freelite-. Immunofixation in serum and urine Analysis to rule out the presence of monoclonal protein in blood and urine. Patients with confirmed ATTR type Cardiac Amyloidosis will undergo a study of mutations in the TTR gene
Hospital Universitario Virgen Macarena
Seville, SEVILLA, 41071, Spain
Prado Salamanca-Bautista, MD, PhD
Hospital Universitario Virgen Macarena
Rocio Ruiz-Hueso, MD
Hospital Universitario Virgen Macarena
First Submitted
November 8, 2021
First Posted
January 4, 2022
Study Start
January 15, 2022
Actual (reported)Primary Completion
March 31, 2024
Actual (reported)The Role of Bioimpedance Analysis in Patients With Chronic Heart Failure and Systolic Ventricular Dysfunction
Contact the study team to confirm eligibility.
Study Completion
December 31, 2025
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
Last Updated
October 1, 2024
Record last verified: 2024-09
Download the complete ClinicalTrials.gov record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.
Source: ClinicalTrials.gov.
JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.
Source retrieved: